drugset / Trial / NCT00982501
WS®1442 in Slightly Overweight Subjects
RandomizedParallel-groupDouble-blind
Summary
The purpose of this study is to test: 1. Safety of 900 mg or 1800 mg of WS® 1442 per day in overweight subjects (BMI 25 to 29,9 kg/m²) 2. Pharmacodynamic effect of WS® 1442 on endothelial function versus nordic walking training in overweight subjects
Timeline
- Start
- 2008-06
- Primary completion
- 2010-09
- Completion
- 2011-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | WS® 1442 | Unknown | 900 mg | — |
| Subject | WS® 1442 | Unknown | 1800 mg | — |